عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Japan Sees Hottest September Since Records Began 

Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)
Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)
TT
TT

Japan Sees Hottest September Since Records Began 

Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)
Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)

Japan has seen its hottest September since records began 125 years ago, the weather agency said, in a year expected to be the warmest in human history.

The scorching September's average temperature was 2.66 degrees Celsius higher than usual, the Japan Meteorological Agency said on Monday.

This was "the highest figure since the start of statistics in 1898", the agency said in a statement.

This year is expected to be the hottest in human history as climate change accelerates, with countries including Austria, France, Germany, Poland and Switzerland each announcing their warmest September on record.

Across Japan last month, 100 of 153 observation locations broke an average temperature record, including in Tokyo, with an all-time high of 26.7 degrees Celsius (80 degrees Fahrenheit), in Osaka with 27.9C and in Nagoya with 27.3C.

The average temperature jump of 2.66C was "extraordinary" and "easily topped previous highs", weather agency official Masayuki Hirai told AFP on Tuesday.

"If this is not an abnormally high temperature, I don't know what is," he said.

French weather authority Meteo-France said the September temperature average in the country will be around 21.5 degrees Celsius, between 3.5C and 3.6C above the 1991-2020 reference period.

The UK, too, has matched its record for the warmest September since records began in 1884.

The average global temperature in June, July and August was 16.77 degrees Celsius, surpassing the previous 2019 record, the European Union's Copernicus Climate Change Service (C3S) said in a report.

In September, UN Secretary-General Antonio Guterres told world leaders the climate crisis had "opened the gates to hell".

In his opening address at the Climate Ambition Summit, Guterres evoked this year's "horrendous heat" but stressed: "We can still limit the rise in global temperature to 1.5 degrees," referring to the target seen as needed to avoid long-term climate catastrophe.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”